The relationship between cholesterol level and Alzheimer’s disease-associated APP proteolysis/Aβ metabolism

References

• Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev 2001;81(2):741–66.
   PubMed Web of Science ®Google Scholar
• Karran E, Mercken M, De Strooper, B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 2011;10(9):698–712.
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Solomon A. Cholesterol as a risk factor for Alzheimer’s disease – epidemiological evidence. Acta Neurol Scand Suppl 2006;185:50–7.
   PubMedGoogle Scholar
• Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer’s disease. Neuroepidemiology 1998;17(1):14–20.
   PubMed Web of Science ®Google Scholar
• Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. Br Med J 2001;322(7300):1447–51.
   PubMed Web of Science ®Google Scholar
• Solomon A, Kivipelto M, Wolozin B, Zhou JF, Whitmer RA. Midlife Serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009;28(1):75–80.
   PubMed Web of Science ®Google Scholar
• Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 2003;61(2):199–205.
   PubMed Web of Science ®Google Scholar
• Luchsinger JA, Tang MX, Shea S, Mayeux R. Caloric intake and the risk of Alzheimer disease. Arch Neurol 2002;59(8):1258–63.
   PubMedGoogle Scholar
• Morris MC, Evans DA, Bienias JL, Tangney CC, Bennett DA, Aggarwal N, et al. Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003;60(2):194–200.
   PubMed Web of Science ®Google Scholar
• Sjogren M, Mielke M, Gustafson D, Zandi P, Skoog I. Cholesterol and Alzheimer’s disease – is there a relation? Mech Ageing Dev 2006;127(2):138–47.
   PubMed Web of Science ®Google Scholar
• Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61(5):705–14.
   PubMedGoogle Scholar
• Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005;64(10):1689–95.
   PubMed Web of Science ®Google Scholar
• Slooter AJ, Cruts M, Ott A, Bots ML, Witteman JC, Hofman A, et al. The effect of APOE on dementia is not through atherosclerosis: the Rotterdam study. Neurology 1999;53(7):1593–5.
   PubMed Web of Science ®Google Scholar
• Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, Breitner JC, et al. Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 2005;65(7):1045–50.
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Leoni V, Meaney S. Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res 2010;51(9):2489–503.
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 2004;24(5):806–15.
   PubMed Web of Science ®Google Scholar
• Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001;12(2):105–12.
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Cedazo-Minguez A, Leoni V, Meaney S. Oxysterols and neurodegenerative diseases. Mol Aspects Med 2009;30(3):171–9.
   PubMed Web of Science ®Google Scholar
• Wood WG, Li L, Muller WE, Eckert GP. Cholesterol as a causative factor in Alzheimer’s disease: a debatable hypothesis. J Neurochem 2014;129(4):559–72.
   PubMed Web of Science ®Google Scholar
• Bjorkhem I, Heverin M, Leoni V, Meaney S, Diczfalusy U. Oxysterols and Alzheimer’s disease. Acta Neurol Scand Suppl 2006;185:43–9.
   PubMedGoogle Scholar
• Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, et al. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer’s disease. J Lipid Res 2004;45(1):186–93.
   PubMed Web of Science ®Google Scholar
• Heverin M, Maioli S, Pham T, Mateos L, Camporesi E, Ali Z, et al. 27-hydroxycholesterol mediates negative effects of dietary cholesterol on cognition in mice. Behav Brain Res 2015;278:356–9.
   PubMed Web of Science ®Google Scholar
• Brooks SW, Dykes AC, Schreurs BG, Ghribi O. A high-cholesterol diet increases 27-hydroxycholesterol and modifies estrogen receptor expression and neurodegeneration in rabbit hippocampus. J Alzheimers Dis 2017;56(1):185–196.
   PubMed Web of Science ®Google Scholar
• Hudry E, Van Dam D, Kulik W, De Deyn PP, Stet FS, Ahouansou O, et al. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer’s disease. Mol Ther 2010;18(1):44–53.
   PubMed Web of Science ®Google Scholar
• Djelti F, Braudeau J, Hudry E, Dhenain M, Varin J, Bieche I, et al. CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer’s disease. Brain 2015;138(8):2383–98.
   PubMedGoogle Scholar
• Leoni V, Masterman T, Diczfalusy U, De Luca G, Hillert J, Bjorkhem I. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci Lett 2002;331(3):163–6.
   PubMed Web of Science ®Google Scholar
• Shafaati M, Marutle A, Pettersson H, Lovgren-Sandblom A, Olin M, Pikuleva I, et al. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer’s patients with the Swedish APP 670/671 mutation. J Lipid Res 2011;52(5):1004–10.
   PubMed Web of Science ®Google Scholar
• Testa G, Staurenghi E, Zerbinati C, Gargiulo S, Iuliano L, Giaccone G, et al. Changes in brain oxysterols at different stages of Alzheimer’s disease: their involvement in neuroinflammation. Redox Biol 2016;10:24–33.
   PubMed Web of Science ®Google Scholar
• Panes O, Gonzalez C, Hidalgo P, Valderas JP, Acevedo M, Contreras S, et al. Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin. Atherosclerosis 2017;257:164–71.
   PubMed Web of Science ®Google Scholar
• Sharma N, Baek K, Phan HTT, Shimokawa N, Takagi M. Glycosyl chains and 25-hydroxycholesterol contribute to the intracellular transport of amyloid beta (Abeta-42) in Jurkat T cells. FEBS Open Bio 2017;7(6):865–76.
   PubMed Web of Science ®Google Scholar
• Locatelli S, Lutjohann D, Schmidt HH, Otto C, Beisiegel U, von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia: evidence that simvastatin affects cholesterol metabolism in the human brain. Arch Neurol 2002;59(2):213–16.
   PubMedGoogle Scholar
• Stuart SA, Robertson JD, Marrion NV, Robinson ES, Skoulakis EMC. Chronic pravastatin but not atorvastatin treatment impairs cognitive function in two rodent models of learning and memory. PLoS One 2013;8(9):e75467.
   PubMed Web of Science ®Google Scholar
• Geifman N, Brinton RD, Kennedy RE, Schneider LS, Butte AJ. Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimers Res Ther 2017;9(1):10.
   PubMed Web of Science ®Google Scholar
• Suraweera C, de Silva V, Hanwella R. Simvastatin-induced cognitive dysfunction: two case reports. J Med Case Rep 2016;10:83.
   PubMedGoogle Scholar
• Glodzik L, Rusinek H, Kamer A, Pirraglia E, Tsui W, Mosconi L, et al. Effects of vascular risk factors, statins, and antihypertensive drugs on PiB deposition in cognitively normal subjects. Alzheimers Dement 2016;2:95–104.
   Google Scholar
• Padala KP, Padala PR, McNeilly DP, Geske JA, Sullivan DH, Potter JF. The effect of HMG-CoA reductase inhibitors on cognition in patients with Alzheimer’s dementia: a prospective withdrawal and rechallenge pilot study. Am J Geriatr Pharmacother 2012;10(5):296–302.
   PubMedGoogle Scholar
• McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2016;(1):CD003160.
   PubMed Web of Science ®Google Scholar
• Jin H, Chen T, Li G, Wang C, Zhang B, Cao X, et al. Dose-Dependent neuroprotection and neurotoxicity of simvastatin through reduction of farnesyl pyrophosphate in mice treated with intracerebroventricular injection of Abeta 1-42. J Alzheimers Dis 2016;50(2):501–16.
   PubMed Web of Science ®Google Scholar
• Goritz C, Mauch DH, Pfrieger FW. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol Cell Neurosci 2005;29(2):190–201.
   PubMed Web of Science ®Google Scholar
• Fester L, Zhou L, Butow A, Huber C, von Lossow R, Prange-Kiel J, et al. Cholesterol-promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. Hippocampus 2009;19(8):692–705.
   PubMed Web of Science ®Google Scholar
• Koudinov AR, Koudinova NV. Cholesterol homeostasis failure as a unifying cause of synaptic degeneration. J Neurol Sci 2005;229–230:233–40.
   PubMedGoogle Scholar
• Orth M, Bellosta S. Cholesterol: its regulation and role in central nervous system disorders. Cholesterol 2012;2012:292598.
   PubMedGoogle Scholar
• Reed B, Villeneuve S, Mack W, DeCarli C, Chui HC, Jagust W. Associations between serum cholesterol levels and cerebral amyloidosis. JAMA Neurol 2014;71(2):195–200.
   PubMed Web of Science ®Google Scholar
• Wolozin B. Cholesterol, statins and dementia. Curr Opin Lipidol 2004;15(6):667–72.
   PubMed Web of Science ®Google Scholar
• Sinha S, Anderson JP, Barbour R, Basi GS, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999;402(6761):537–40.
   PubMed Web of Science ®Google Scholar
• Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999;286(5440):735–41.
   PubMed Web of Science ®Google Scholar
• Yan R, Bienkowski MJ, Shuck ME, Miao H, Tory MC, Pauley AM, et al. Membrane-anchored aspartyl protease with Alzheimer’s disease beta-secretase activity. Nature 1999;402(6761):533–7.
   PubMed Web of Science ®Google Scholar
• Farzan M, Schnitzler CE, Vasilieva N, Leung D, Choe H. BACE2, a beta-secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein. Proc Natl Acad Sci USA 2000;97(17):9712–17.
   PubMed Web of Science ®Google Scholar
• Roberds SL, Anderson J, Basi G, Bienkowski MJ, Branstetter DG, Chen KS, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet 2001;10(12):1317–24.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 2005;19(1–2):237–42.
   PubMed Web of Science ®Google Scholar
• Irizarry MC. Biomarkers of Alzheimer disease in plasma. NeuroRx 2004;1(2):226–34.
   PubMedGoogle Scholar
• Ghribi O, Larsen B, Schrag M, Herman MM. High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 2006;200(2):460–7.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS. A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med 1998;4(6):730–4.
   PubMed Web of Science ®Google Scholar
• Morishima-Kawashima M, Ihara Y. The presence of amyloid beta-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 1998;37(44):15247–53.
   PubMed Web of Science ®Google Scholar
• Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95(11):6460–4.
   PubMed Web of Science ®Google Scholar
• Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer’s disease. Mol Membr Biol 2006;23(1):111–22.
   PubMed Web of Science ®Google Scholar
• Hattori C, Asai M, Onishi H, Sasagawa N, Hashimoto Y, Saido TC, et al. BACE1 interacts with lipid raft proteins. J Neurosci Res 2006;84(4):912–17.
   PubMed Web of Science ®Google Scholar
• Marquer C, Devauges V, Cossec JC, Liot G, Lecart S, Saudou F, et al. Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J 2011;25(4):1295–305.
   PubMed Web of Science ®Google Scholar
• Lisanti MP, Scherer PE, Tang Z, Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol 1994;4(7):231–5.
   PubMedGoogle Scholar
• Bickel PE, Scherer PE, Schnitzer JE, Oh P, Lisanti MP, Lodish HF. Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem 1997;272(21):13793–802.
   PubMed Web of Science ®Google Scholar
• Kern A, Roempp B, Prager K, Walter J, Behl C. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. J Biol Chem 2006;281(5):2405–13.
   PubMed Web of Science ®Google Scholar
• Buxbaum JD, Liu KN, Luo Y, Slack JL, Stocking KL, Peschon JJ, et al. Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 1998;273(43):27765–7.
   PubMed Web of Science ®Google Scholar
• Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, et al. Constitutive and regulated alpha-secretase cleavage of Alzheimer’s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci USA 1999;96(7):3922–7.
   PubMed Web of Science ®Google Scholar
• Asai M, Hattori C, Szabo B, Sasagawa N, Maruyama K, Tanuma S, et al. Putative function of ADAM9, ADAM10, and ADAM17 as APP alpha-secretase. Biochem Biophys Res Commun 2003;301(1):231–5.
   PubMed Web of Science ®Google Scholar
• Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, et al. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J 2010;29(17):3020–32.
   PubMed Web of Science ®Google Scholar
• Furukawa K, Sopher BL, Rydel RE, Begley JG, Pham DG, Martin GM, et al. Increased activity-regulating and neuroprotective efficacy of alpha-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J Neurochem 1996;67(5):1882–96.
   PubMed Web of Science ®Google Scholar
• Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, et al. Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 1998;95(21):12683–8.
   PubMed Web of Science ®Google Scholar
• Stein TD, Anders NJ, DeCarli C, Chan SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPSW mice resulting in tau phosphorylation and loss of hippocampal neurons: support for the amyloid hypothesis. J Neurosci 2004;24(35):7707–17.
   PubMed Web of Science ®Google Scholar
• Dulin F, Leveille F, Ortega JB, Mornon JP, Buisson A, Callebaut I, et al. P3 peptide, a truncated form of A beta devoid of synaptotoxic effect, does not assemble into soluble oligomers. FEBS Lett 2008;582(13):1865–70.
   PubMed Web of Science ®Google Scholar
• Lim HJ, Shim SB, Jee SW, Lee SH, Lim CJ, Hong JT, et al. Green tea catechin leads to global improvement among Alzheimer’s disease-related phenotypes in NSE/hAPP-C105 Tg mice. J Nutr Biochem 2013;24(7):1302–13.
   PubMed Web of Science ®Google Scholar
• Yao ZX, Papadopoulos V. Function of beta-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J 2002;16(12):1677–9.
   PubMed Web of Science ®Google Scholar
• Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003;278(40):38829–39.
   PubMed Web of Science ®Google Scholar
• Reiss K, Cornelsen I, Husmann M, Gimpl G, Bhakdi S. Unsaturated fatty acids drive disintegrin and metalloproteinase (ADAM)-dependent cell adhesion, proliferation, and migration by modulating membrane fluidity. J Biol Chem 2011;286(30):26931–42.
   PubMed Web of Science ®Google Scholar
• Wang J, Ohno-Matsui K, Morita I. Cholesterol enhances amyloid beta deposition in mouse retina by modulating the activities of Abeta-regulating enzymes in retinal pigment epithelial cells. Biochem Biophys Res Commun 2012;424(4):704–9.
   PubMed Web of Science ®Google Scholar
• Chen YL, Wang LM, Chen Y, Gao JY, Marshall C, Cai ZY, et al. Changes in astrocyte functional markers and beta-amyloid metabolism-related proteins in the early stages of hypercholesterolemia. Neuroscience 2016;316:178–91.
   PubMed Web of Science ®Google Scholar
• Wolfe MS. The gamma-secretase complex: membrane-embedded proteolytic ensemble. Biochemistry 2006;45(26):7931–9.
   PubMed Web of Science ®Google Scholar
• De Strooper B, Saftig P, Craessaerts K, Vanderstichele H, Guhde GW, Von Figura K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor. Nature 1998;391(6665):387–90.
   PubMed Web of Science ®Google Scholar
• Thimiri Govinda Raj DB, Ghesquiere B, Tharkeshwar AK, Coen K, Derua R, Vanderschaeghe D, et al. A novel strategy for the comprehensive analysis of the biomolecular composition of isolated plasma membranes. Mol Syst Biol 2011;7:541.
   PubMed Web of Science ®Google Scholar
• Walter J. gamma-Secretase, apolipoprotein E and cellular cholesterol metabolism. Curr Alzheimer Res 2012;9(2):189–99.
   PubMed Web of Science ®Google Scholar
• Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997;89(3):331–40.
   PubMed Web of Science ®Google Scholar
• Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of gamma-secretase by its lipid microenvironment. J Biol Chem 2008;283(33):22529–40.
   PubMed Web of Science ®Google Scholar
• Amtul Z, Westaway D, Cechetto DF, Rozmahel RF. Oleic acid ameliorates amyloidosis in cellular and mouse models of Alzheimer’s disease. Brain Pathol 2011;21(3):321–9.
   PubMed Web of Science ®Google Scholar
• Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, et al. Cholesterol retention in Alzheimer’s brain is responsible for high beta- and gamma-secretase activities and Abeta production. Neurobiol Dis 2008;29(3):422–37.
   PubMed Web of Science ®Google Scholar
• Wahrle S, Das P, Nyborg AC, McLendon C, Shoji M, Kawarabayashi T, et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 2002;9(1):11–23.
   PubMed Web of Science ®Google Scholar
• Hur JY, Welander H, Behbahani H, Aoki M, Franberg J, Winblad B, et al. Active gamma-secretase is localized to detergent-resistant membranes in human brain. FEBS J 2008;275(6):1174–87.
   PubMed Web of Science ®Google Scholar
• Eckert GP, Muller WE. Presenilin 1 modifies lipid raft composition of neuronal membranes. Biochem Biophys Res Commun 2009;382(4):673–7.
   PubMed Web of Science ®Google Scholar
• Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature 1987;325(6106):733–6.
   PubMed Web of Science ®Google Scholar
• Ewald CY, Li C. Understanding the molecular basis of Alzheimer’s disease using a Caenorhabditis elegans model system brain. Struct Funct 2010;214(2–3):263–83.
   PubMed Web of Science ®Google Scholar
• Ewald CY, Li C. Caenorhabditis elegans as a model organism to study APP function. Exp Brain Res 2012;217(3–4):397–411.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Oishi M, Marshak DR, Czernik AJ, Nairn AC, Greengard P. Cell cycle-dependent regulation of the phosphorylation and metabolism of the Alzheimer amyloid precursor protein. EMBO J 1994;13(5):1114–22.
   PubMed Web of Science ®Google Scholar
• Oishi M, Nairn AC, Czernik AJ, Lim GS, Isohara T, Gandy SE, et al. The cytoplasmic domain of Alzheimer’s amyloid precursor protein is phosphorylated at Thr654, Ser655, and Thr668 in adult rat brain and cultured cells. Mol Med 1997;3(2):111–23.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ando K, Isohara T, Oishi M, Lim GS, Satoh Y, et al. Phosphorylation of Alzheimer beta-amyloid precursor-like proteins. Biochemistry 1997;36(15):4643–9.
   PubMed Web of Science ®Google Scholar
• Isohara T, Horiuchi A, Watanabe T, Ando K, Czernik AJ, Uno I, et al. Phosphorylation of the cytoplasmic domain of Alzheimer’s beta-amyloid precursor protein at Ser655 by a novel protein kinase. Biochem Biophys Res Commun 1999;258(2):300–5.
   PubMed Web of Science ®Google Scholar
• Iijima K, Ando K, Takeda S, Satoh Y, Seki T, Itohara S, et al. Neuron-specific phosphorylation of Alzheimer’s beta-amyloid precursor protein by cyclin-dependent kinase 5. J Neurochem 2000;75(3):1085–91.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Ando K, Iijima K, Oguchi S, Takeda S. Phosphorylation of amyloid precursor protein (APP) family proteins methods. Mol Med 2000;32:271–82.
   Google Scholar
• da Cruz e Silva EF, da Cruz e Silva OA. Protein phosphorylation and APP metabolism. Neurochem Res 2003;28(10):1553–61.
   PubMed Web of Science ®Google Scholar
• Sano Y, Nakaya T, Pedrini S, Takeda S, Iijima-Ando K, Iijima K, et al. Physiological mouse brain Abeta levels are not related to the phosphorylation state of threonine-668 of Alzheimer’s APP. PLoS One 2006;1:e51.
   PubMed Web of Science ®Google Scholar
• Ando K, Iijima KI, Elliott JI, Kirino Y, Suzuki T. Phosphorylation-dependent regulation of the interaction of amyloid precursor protein with Fe65 affects the production of beta-amyloid. J Biol Chem 2001;276(43):40353–61.
   PubMed Web of Science ®Google Scholar
• Seeger M, Nordstedt C, Petanceska S, Kovacs DM, Gouras GK, Hahne S, et al. Evidence for phosphorylation and oligomeric assembly of presenilin 1. Proc Natl Acad Sci USA 1997;94(10):5090–4.
   PubMed Web of Science ®Google Scholar
• Walter J, Schindzielorz A, Grunberg J, Haass C. Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis. Proc Natl Acad Sci USA 1999;96(4):1391–6.
   PubMed Web of Science ®Google Scholar
• Pastorino L, Ikin AF, Nairn AC, Pursnani A, Buxbaum JD. The carboxyl-terminus of BACE contains a sorting signal that regulates BACE trafficking but not the formation of total A(beta). Mol Cell Neurosci 2002;19(2):175–85.
   PubMed Web of Science ®Google Scholar
• Fluhrer R, Friedlein A, Haass C, Walter J. Phosphorylation of presenilin 1 at the caspase recognition site regulates its proteolytic processing and the progression of apoptosis. J Biol Chem 2004;279(3):1585–93.
   PubMed Web of Science ®Google Scholar
• von Arnim CA, Tangredi MM, Peltan ID, Lee BM, Irizarry MC, Kinoshita A, et al. Demonstration of BACE (beta-secretase) phosphorylation and its interaction with GGA1 in cells by fluorescence-lifetime imaging microscopy. J Cell Sci 2004;117(Pt 22):5437–45.
   PubMed Web of Science ®Google Scholar
• Ghareeb DA, Khalil S, Hafez HS, Bajorath J, Ahmed HE, Sarhan E, et al. Berberine reduces neurotoxicity related to nonalcoholic steatohepatitis in rats. Evid Based Complement Alternat Med 2015;2015:361847.
   PubMedGoogle Scholar
• Huttunen HJ, Puglielli L, Ellis BC, MacKenzie Ingano LA, Kovacs DM. Novel N-terminal cleavage of APP precludes Abeta generation in ACAT-defective AC29 cells. J Mol Neurosci 2009;37(1):6–15.
   PubMed Web of Science ®Google Scholar
• Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, et al. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Nat Cell Biol 2001;3(10):905–12.
   PubMed Web of Science ®Google Scholar
• Abad-Rodriguez J, Ledesma MD, Craessaerts K, Perga S, Medina M, Delacourte A, et al. Neuronal membrane cholesterol loss enhances amyloid peptide generation. J Cell Biol 2004;167(5):953–60.
   PubMed Web of Science ®Google Scholar
• Beel AJ, Sakakura M, Barrett PJ, Sanders CR. Direct binding of cholesterol to the amyloid precursor protein: an important interaction in lipid-Alzheimer’s disease relationships? Biochim Biophys Acta 2010;1801(8):975–82.
   PubMed Web of Science ®Google Scholar
• Bodovitz S, Klein WL. Cholesterol modulates alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 1996;271(8):4436–40.
   PubMed Web of Science ®Google Scholar
• Loffler T, Schweinzer C, Flunkert S, Santha M, Windisch M, Steyrer E, et al. Brain cortical cholesterol metabolism is highly affected by human APP overexpression in mice. Mol Cell Neurosci 2016;74:34–41.
   PubMed Web of Science ®Google Scholar
• Mody N, Agouni A, McIlroy GD, Platt B, Delibegovic M. Susceptibility to diet-induced obesity and glucose intolerance in the APP (SWE)/PSEN1 (A246E) mouse model of Alzheimer’s disease is associated with increased brain levels of protein tyrosine phosphatase 1B (PTP1B) and retinol-binding protein 4 (RBP4), and basal phosphorylation of S6 ribosomal protein. Diabetologia 2011;54(8):2143–51.
   PubMed Web of Science ®Google Scholar
• Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, et al. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007;56(1):66–78.
   PubMed Web of Science ®Google Scholar
• Rushworth JV, Hooper NM. Lipid rafts: linking Alzheimer’s amyloid-beta production, aggregation, and toxicity at neuronal membranes. Int J Alzheimers Dis 2010;2011:603052.
   PubMedGoogle Scholar
• Ariga T, Wakade C, Yu RK. The pathological roles of ganglioside metabolism in Alzheimer’s disease: effects of gangliosides on neurogenesis. Int J Alzheimers Dis 2011;2011:193618.
   PubMedGoogle Scholar
• Kakio A, Nishimoto SI, Yanagisawa K, Kozutsumi Y, Matsuzaki K. Cholesterol-dependent formation of GM1 ganglioside-bound amyloid beta-protein, an endogenous seed for Alzheimer amyloid. J Biol Chem 2001;276(27):24985–90.
   PubMed Web of Science ®Google Scholar
• Fantini J, Yahi N, Garmy N. Cholesterol accelerates the binding of Alzheimer’s beta-amyloid peptide to ganglioside GM1 through a universal hydrogen-bond-dependent sterol tuning of glycolipid conformation. Front Physiol 2013;4:120.
   PubMed Web of Science ®Google Scholar
• Yuyama K, Yanagisawa K. Sphingomyelin accumulation provides a favorable milieu for GM1 ganglioside-induced assembly of amyloid beta-protein. Neurosci Lett 2010;481(3):168–72.
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Zlokovic BV. RAGE (yin) versus LRP (yang) balance regulates Alzheimer amyloid beta-peptide clearance through transport across the blood-brain barrier. Stroke 2004;35(11 Suppl 1):2628–31.
   PubMed Web of Science ®Google Scholar
• Zlokovic BV. Clearing amyloid through the blood-brain barrier. J Neurochem 2004;89(4):807–11.
   PubMed Web of Science ®Google Scholar
• Jeynes B, Provias J. Evidence for altered LRP/RAGE expression in Alzheimer lesion pathogenesis. Curr Alzheimer Res 2008;5(5):432–7.
   PubMed Web of Science ®Google Scholar
• May P, Herz J. LDL receptor-related proteins in neurodevelopment. Traffic 2003;4(5):291–301.
   PubMed Web of Science ®Google Scholar
• Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004;43(3):333–44.
   PubMed Web of Science ®Google Scholar
• Jaya Prasanthi RP, Schommer E, Thomasson S, Thompson A, Feist G, Ghribi O. Regulation of beta-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer’s disease. Mech Ageing Dev 2008;129(11):649–55.
   PubMed Web of Science ®Google Scholar
• Llorente-Cortes V, Casani L, Cal R, Llenas A, Juan-Babot O, Camino-Lopez S, et al. Cholesterol-lowering strategies reduce vascular LRP1 overexpression induced by hypercholesterolaemia. Eur J Clin Invest 2011;41(10):1087–97.
   PubMed Web of Science ®Google Scholar
• Rapp A, Gmeiner B, Huttinger M. Implication of apoE isoforms in cholesterol metabolism by primary rat hippocampal neurons and astrocytes. Biochimie 2006;88(5):473–83.
   PubMed Web of Science ®Google Scholar
• Yan SD, Roher A, Chaney M, Zlokovic B, Schmidt AM, Stern D. Cellular cofactors potentiating induction of stress and cytotoxicity by amyloid beta-peptide. Biochim Biophys Acta 2000;1502(1):145–57.
   PubMed Web of Science ®Google Scholar
• Leclerc E, Sturchler E, Vetter SW. The S100B/RAGE axis in Alzheimer’s disease. Cardiovasc Psychiatry Neurol 2010;2010:539581.
   PubMedGoogle Scholar
• Ishibashi S, Herz J, Maeda N, Goldstein JL, Brown MS. The two-receptor model of lipoprotein clearance: tests of the hypothesis in ‘knockout’ mice lacking the low density lipoprotein receptor, apolipoprotein E, or both proteins. Proc Natl Acad Sci USA 1994;91(10):4431–5.
   PubMed Web of Science ®Google Scholar
• Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 2000;74(3):1008–16.
   PubMed Web of Science ®Google Scholar
• Lee CY, Tse W, Smith JD, Landreth GE. Apolipoprotein E promotes beta-amyloid trafficking and degradation by modulating microglial cholesterol levels. J Biol Chem 2012;287(3):2032–44.
   PubMed Web of Science ®Google Scholar
• Fukami S, Watanabe K, Iwata N, Haraoka J, Lu B, Gerard NP, et al. Abeta-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Abeta pathology. Neurosci Res 2002;43(1):39–56.
   PubMed Web of Science ®Google Scholar
• Eckman EA, Eckman CB. Abeta-degrading enzymes: modulators of Alzheimer’s disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 2005;33(Pt 5):1101–5.
   PubMedGoogle Scholar
• Carrasquillo MM, Belbin O, Zou F, Allen M, Ertekin-Taner N, Ansari M, et al. Concordant association of insulin degrading enzyme gene (IDE) variants with IDE mRNA, Abeta, and Alzheimer’s disease. PLoS One 2010;5(1):e8764.
   PubMed Web of Science ®Google Scholar
• Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003;100(7):4162–7.
   PubMed Web of Science ®Google Scholar
• Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003;40(6):1087–93.
   PubMed Web of Science ®Google Scholar
• Caravaggio JW, Hasu M, MacLaren R, Thabet M, Raizman JE, Veinot JP, et al. Insulin-degrading enzyme deficiency in bone marrow cells increases atherosclerosis in LDL receptor-deficient mice. Cardiovasc Pathol 2013;22(6):458–64.
   PubMed Web of Science ®Google Scholar
• Ettcheto M, Petrov D, Pedros I, de Lemos L, Pallas M, Alegret M, et al. Hypercholesterolemia and neurodegeneration. Comparison of hippocampal phenotypes in LDLr knockout and APPswe/PS1dE9 mice. Exp Gerontol 2015;65:69–78.
   PubMed Web of Science ®Google Scholar
• Bulloj A, Leal MC, Surace EI, Zhang X, Xu H, Ledesma MD, et al. Detergent resistant membrane-associated IDE in brain tissue and cultured cells: relevance to Abeta and insulin degradation. Mol Neurodegener 2008;3:22.
   PubMed Web of Science ®Google Scholar
• Hama E, Shirotani K, Iwata N, Saido TC. Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid beta peptide clearance in primary neurons. J Biol Chem 2004;279(29):30259–64.
   PubMed Web of Science ®Google Scholar
• Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain Abeta by neprilysin. Science 2001;292(5521):1550–2.
   PubMed Web of Science ®Google Scholar
• Shirotani K, Tsubuki S, Iwata N, Takaki Y, Harigaya W, Maruyama K, et al. Neprilysin degrades both amyloid beta peptides 1-40 and 1-42 most rapidly and efficiently among thiorphan- and phosphoramidon-sensitive endopeptidases. J Biol Chem 2001;276(24):21895–901.
   PubMed Web of Science ®Google Scholar
• Iwata N, Sekiguchi M, Hattori Y, Takahashi A, Asai M, Ji B, et al. Global brain delivery of neprilysin gene by intravascular administration of AAV vector in mice. Sci Rep 2013;3:1472.
   PubMed Web of Science ®Google Scholar
• Kanemitsu H, Tomiyama T, Mori H. Human neprilysin is capable of degrading amyloid beta peptide not only in the monomeric form but also the pathological oligomeric form. Neurosci Lett 2003;350(2):113–16.
   PubMed Web of Science ®Google Scholar
• Helisalmi S, Hiltunen M, Vepsalainen S, Iivonen S, Mannermaa A, Lehtovirta M, et al. Polymorphisms in neprilysin gene affect the risk of Alzheimer’s disease in Finnish patients. J Neurol Neurosurg Psychiatry 2004;75(12):1746–8.
   PubMed Web of Science ®Google Scholar
• Wood LS, Pickering EH, McHale D, Dechairo BM. Association between neprilysin polymorphisms and sporadic Alzheimer’s disease. Neurosci Lett 2007;427(2):103–6.
   PubMed Web of Science ®Google Scholar
• Vepsalainen S, Helisalmi S, Mannermaa A, Pirttila T, Soininen H, Hiltunen M. Combined risk effects of IDE and NEP gene variants on Alzheimer disease. J Neurol Neurosurg Psychiatry 2009;80(11):1268–70.
   PubMed Web of Science ®Google Scholar
• Maesako M, Uemura K, Kubota M, Kuzuya A, Sasaki K, Hayashida N, et al. Exercise is more effective than diet control in preventing high fat diet-induced beta-amyloid deposition and memory deficit in amyloid precursor protein transgenic mice. J Biol Chem 2012;287(27):23024–33.
   PubMed Web of Science ®Google Scholar
• Nagai N, Ito Y, Tanino T. Effect of high glucose levels on amyloid beta production in retinas of spontaneous diabetes mellitus Otsuka Long-Evans Tokushima fatty rats. Biol Pharm Bull 2015;38(4):601–10.
   PubMed Web of Science ®Google Scholar
• Grimm MO, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T. Neprilysin and Abeta clearance: impact of the APP intracellular domain in NEP regulation and implications in Alzheimer’s disease. Front Aging Neurosci 2013;5:98.
   PubMed Web of Science ®Google Scholar